Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

Trial Details

NCT ID
NCT06831136
Phase
PHASE2
Sponsor
The University of Texas Health Science Center, Houston
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Neoadjuvant Chemotherapy (NAC)
  • Immunotherapy (pembrolizumab)
  • Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Is willing and able to comply with the protocol for the duration of the study,including undergoing treatment and scheduled visits and examinations,…
  • Biopsy-proven locally advanced unresectable or metastatic PDAC
  • Patients who have undergone prior resection will be excluded unless there is recurrent pancreatic tumor that is amenable to EUS-RFA.
  • If biliary metal stent is placed, during procedure of EUS-RFA, indwelling biliary metal stent will be removed during initial EUS-RFA and then repla…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →